CAR-T cell manufacturing: Major process parameters and next-generation strategies
University of California, Los Angeles · Parker Institute for Cancer Immunotherapy · +1 more institution
Abstract
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Citation impact
- FWCI
- 62.03
- Percentile
- 100%
- References
- 153
Authors
5- MAMelanie Ayala Ceja
University of California, Los Angeles
- MKMobina Khericha
University of California, Los Angeles
- CHCaitlin Harris
University of California, Los Angeles
- CPCristina Puig-Saus
University of California, Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA Jonsson Comprehensive Cancer Center
- YYYvonne Y. ChenCorresponding
University of California, Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA Jonsson Comprehensive Cancer Center
Topics & keywords
- Chimeric antigen receptor
- Manufacturing process
- Process (computing)
- Cell
- Medicine
- Immunotherapy
- Business
- Computer science